RS66934B1 - Jedinjenja za upotrebu u lečenju poremećaja pažnje sa hiperaktivnošću - Google Patents

Jedinjenja za upotrebu u lečenju poremećaja pažnje sa hiperaktivnošću

Info

Publication number
RS66934B1
RS66934B1 RS20250624A RSP20250624A RS66934B1 RS 66934 B1 RS66934 B1 RS 66934B1 RS 20250624 A RS20250624 A RS 20250624A RS P20250624 A RSP20250624 A RS P20250624A RS 66934 B1 RS66934 B1 RS 66934B1
Authority
RS
Serbia
Prior art keywords
compound
adhd
use according
formula
administered
Prior art date
Application number
RS20250624A
Other languages
English (en)
Serbian (sr)
Inventor
Karl Ægir Karlsson
Haraldur Þorsteinsson
Original Assignee
3Z Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2101292.7A external-priority patent/GB202101292D0/en
Priority claimed from GBGB2101291.9A external-priority patent/GB202101291D0/en
Priority claimed from GBGB2101296.8A external-priority patent/GB202101296D0/en
Application filed by 3Z Ehf filed Critical 3Z Ehf
Publication of RS66934B1 publication Critical patent/RS66934B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20250624A 2021-01-29 2022-01-28 Jedinjenja za upotrebu u lečenju poremećaja pažnje sa hiperaktivnošću RS66934B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2101292.7A GB202101292D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101291.9A GB202101291D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101296.8A GB202101296D0 (en) 2021-01-29 2021-01-29 Novel treatments
EP22708379.7A EP4284356B1 (en) 2021-01-29 2022-01-28 Compounds for use in the treatment of attention deficit hyperactivity disorder
PCT/EP2022/052142 WO2022162199A2 (en) 2021-01-29 2022-01-28 Novel treatments

Publications (1)

Publication Number Publication Date
RS66934B1 true RS66934B1 (sr) 2025-07-31

Family

ID=80682355

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20250624A RS66934B1 (sr) 2021-01-29 2022-01-28 Jedinjenja za upotrebu u lečenju poremećaja pažnje sa hiperaktivnošću

Country Status (12)

Country Link
US (1) US20240130995A1 (https=)
EP (1) EP4284356B1 (https=)
JP (1) JP2024508372A (https=)
AU (1) AU2022215118A1 (https=)
CA (1) CA3206935A1 (https=)
ES (1) ES3038949T3 (https=)
HR (1) HRP20250747T1 (https=)
HU (1) HUE071725T2 (https=)
PL (1) PL4284356T3 (https=)
RS (1) RS66934B1 (https=)
SM (1) SMT202500238T1 (https=)
WO (1) WO2022162199A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025093748A1 (en) * 2023-11-03 2025-05-08 3Z Pharmaceuticals Use of a calcium channel blocker in the treatment of adhd

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1030672A1 (en) * 1997-11-19 2000-08-30 Merck & Co., Inc. Method for treating attention deficit disorder
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
CA2546395A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
WO2011100659A2 (en) * 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
PL2895507T3 (pl) * 2012-09-11 2019-04-30 Inst Catalana De Recerca I Estudis Avancats Sposób diagnostyczny do wykrywania choroby autoimmunologicznej oraz przedmioty z nim związane
WO2014133329A1 (ko) * 2013-02-27 2014-09-04 에스케이케미칼 주식회사 관절염 치료용 복합 제제
KR20140135676A (ko) * 2014-10-02 2014-11-26 한국과학기술원 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물
JP2021500416A (ja) * 2017-10-27 2021-01-07 エステベ ファーマスーティカルズ，ソシエダッド アノニマ 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions

Also Published As

Publication number Publication date
CA3206935A1 (en) 2022-08-04
SMT202500238T1 (it) 2025-07-22
PL4284356T3 (pl) 2025-07-28
JP2024508372A (ja) 2024-02-27
WO2022162199A2 (en) 2022-08-04
EP4284356A2 (en) 2023-12-06
HUE071725T2 (hu) 2025-09-28
HRP20250747T1 (hr) 2025-08-15
AU2022215118A1 (en) 2023-08-17
AU2022215118A9 (en) 2024-05-16
EP4284356B1 (en) 2025-04-02
EP4284356C0 (en) 2025-04-02
US20240130995A1 (en) 2024-04-25
WO2022162199A3 (en) 2022-09-15
ES3038949T3 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
US20210401776A1 (en) Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
CN107835695B (zh) 用于治疗自闭症的组合物和方法
US20170304351A1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
JP2024530007A (ja) 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの使用
US9271995B2 (en) Agent for ameliorating brain hypofunction
RS66934B1 (sr) Jedinjenja za upotrebu u lečenju poremećaja pažnje sa hiperaktivnošću
US20230115839A1 (en) Methods For Treating Hypersomnia
KR20070085973A (ko) 수면 장애 예방 또는 치료제
US20240002369A1 (en) Novel treatments of attention deficit/hyperactivity disorder
JP2025510790A (ja) 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途
CN111712239A (zh) 治疗不宁腿综合征的治疗剂
HK40101538A (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
HK40101538B (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
WO2025093748A1 (en) Use of a calcium channel blocker in the treatment of adhd
CN116981460A (zh) 注意力缺陷/多动障碍的新颖治疗
CA3086945A1 (en) Variants of 2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid for use in the treatment, prevention and/or amelioration of brain diseases
CN117120046A (zh) 用于治疗注意力缺陷多动障碍的化合物
CN117942336A (zh) Go6976在用于制备抗抑郁药物中的应用
Kamath Study of Anticonvulsant Effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model in Albino Mice
ITBO950086A1 (it) Uso di 2, 3-diidro-4(1h)-chinazolinoni e di composizioni farmaceutiche che li contengono nel trattamento dei disturbi